DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Cantor Fitzgerald Upgrades Novavax to Overweight, Raises Price Target to $16

Cantor Fitzgerald analyst Charles Duncan upgrades Novavax (NASDAQ:NVAX) from Neutral to Overweight and raises the price target from $6 to $16.

Benzinga · 03/17/2020 10:40

Cantor Fitzgerald analyst Charles Duncan upgrades Novavax (NASDAQ:NVAX) from Neutral to Overweight and raises the price target from $6 to $16.